Retinopathy of Prematurity Reactivated 28 Months after Injection of Ranibizumab

Ophthalmol Retina. 2019 Oct;3(10):913-915. doi: 10.1016/j.oret.2019.06.017. Epub 2019 Jul 9.

Authors

Marco H Ji¹, Darius M Moshfeghi², Natalia F Callaway¹, Zachary Bodnar¹, Ira H Schachar¹, Giulia M Amorelli³, Lorenzo Orazi⁴, Fernando Molle³, Domenico Lepore³

Affiliations

¹ Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California.
² Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California. Electronic address: dariusm@stanford.edu.
³ Department of Ophthalmology, Catholic University of Sacred Heart, Rome, Italy.
⁴ Italian National Center of Services and Research for Prevention of Blindness and Rehabilitation of the Visually Impaired, Rome, Italy.

PMID: 31474514
DOI: 10.1016/j.oret.2019.06.017

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Infant, Newborn
Intravitreal Injections
Male
Ranibizumab / administration & dosage
Ranibizumab / adverse effects*
Recurrence
Retina / pathology*
Retinopathy of Prematurity / diagnosis
Retinopathy of Prematurity / drug therapy
Retinopathy of Prematurity / etiology*
Time Factors
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Ranibizumab